Pfizer has entered into an agreement to acquire Encysive Pharmaceuticals, Inc., a publicly held biopharma company, for an equity value of approximately $195 million. Pfizer will acquire the rights to Thelin, an oral, endothelin A receptor antagonist (ETRA) for the treatment of pulmonary arterial hypertension (PAH), as well as Encysive’s other pipeline candidates. Thelin is approved for marketing in the EU and is currently available in the UK, Germany, Ireland, Spain, France, Italy, Belg...